Ally Bridge Group
Overview
Ally Bridge Group is a global healthcare investment firm focused on private and public high-impact life science innovation . Founded in 2013 by Frank Yu, the firm has led or co-led over $6 billion in healthcare transactions . The firm's mission is to generate superior risk-adjusted returns for investors guided by the core principle of selective investment in healthcare innovation that addresses unmet medical needs . Ally Bridge Group has offices in New York and Hong Kong .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| AdvanCell | Jul 2026 | Series D | Lead |
| Climb Bio, Inc. | May 2026 | Private Placement | Co-investor |
| Calyxo | Apr 2026 | Series F | Lead |
| Imperative Care | Mar 2026 | VC Round | Co-investor |
| Precision IO Group Inc. | Feb 2026 | Corporate Funding | Lead |
Key People
Frank Yu
Founder, CEO CIO
Slanix Paul Alex
President Portfolio Manager, Public Equity
Zain Shekhani
Managing Director, Head Of Investor Relations
Dayu Teng
Scientific Advisor Venture Partner
Carlos E. Solorzano
Principal
Tinnie Chau
Principal
Elina Fu
Investor Relations Associate
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
